Botanical Ingredient

Troxerutin Safety Tips

Handling of Troxerutin should only be performed by personnel trained and familiar with handling of potent active pharmaceutical ingredients. Moderate to severe irritant to the skin and eyes.

References

• 1. Phlebotonics for haemorrhoids.
  Perera N, Liolitsa D, Iype S, Croxford A, Yassin M, Lang P, Ukaegbu O, van Issum C.Cochrane Database Syst Rev. 2012 Aug 15;8:CD004322. doi: 10.1002/14651858.CD004322.pub3. Review.
• 2. Radioprotective effects of troxerutin against gamma irradiation in mice liver.
  Ping X, Junqing J, Junfeng J, Enjin J.Int J Radiat Biol. 2012 Aug;88(8):607-12. doi: 10.3109/09553002.2012.692494. Epub 2012 Jun 21.
• 3. Radioprotective effects of troxerutin against gamma irradiation in V79 cells and mice.
  Ping X, Junqing J, Junfeng J, Enjin J.Asian Pac J Cancer Prev. 2011;12(10):2593-6.
• 4. Venoruton®: post thrombotic syndrome. Clinical improvement in venous insufficiency (signs and symptoms) with Venoruton®. A five-year, open-registry, efficacy study.
  Ippolito E, Belcaro G, Dugall M, Cesarone MR, Feragalli B, Errichi BM, Gizzi G, Pellegrini L, Ledda A, Luzzi R, Ricci A, Bavera P, Hosoi M, Corsi M, Errichi S.Panminerva Med. 2011 Sep;53(3 Suppl 1):13-9.
• 5. Battling brain diabetes: antioxidants may reduce cognitive deficits induced by cholesterol.
  Tomycz ND, Friedlander RM.Neurosurgery. 2011 Jun;68(6):N15-7. doi: 10.1227/01.neu.0000398207.79197.5d. Review. No abstract is available.
• 6. [Effect of troxerutin and cerebroproptein hydrolysate injection on platelet aggregation and thrombosis].
  Chen QC, Yu ZJ, Sun HG, Yu JK, Wei MJ.Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Feb;19(1):193-6. Chinese.
• 7. Combination of flavonoids with Centella asiatica and Melilotus for diabetic cystoid macular edema without macular thickening.
  Forte R, Cennamo G, Finelli ML, Bonavolontà P, de Crecchio G, Greco GM.J Ocul Pharmacol Ther. 2011 Apr;27(2):109-13. doi: 10.1089/jop.2010.0159. Epub 2011 Feb 12.
• 8. Troxerutin protects against high cholesterol-induced cognitive deficits in mice.
  Lu J, Wu DM, Zheng ZH, Zheng YL, Hu B, Zhang ZF.Brain. 2011 Mar;134(Pt 3):783-97. doi: 10.1093/brain/awq376. Epub 2011 Jan 19.
• 9. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions.
  Perrin M, Ramelet AA.Eur J Vasc Endovasc Surg. 2011 Jan;41(1):117-25. doi: 10.1016/j.ejvs.2010.09.025. Epub 2010 Dec 3. Review.
• 10. Varicose veins of lower extremities in pregnant women and birth outcomes.
  Bánhidy F, Acs N, Puhó EH, Czeizel AE.Cent Eur J Public Health. 2010 Sep;18(3):161-8.
• 11. Clinical improvement in chronic venous insufficiency signs and symptoms with Venoruton® (HR): an 8-month, open-registry, cost-efficacy study.
  Cesarone MR, Belcaro G, Ippolito E, Pellegrini L, Ledda A, Luzzi R, Ricci A, Dugall M, Bavera P, Hosoi M, Stuard S, Corsi M.Panminerva Med. 2010 Jun;52(2 Suppl 1):43-8.
• 12. Pharmacological treatment in patients with C4, C5 and C6 venous disease.
  Gohel MS, Davies AH.Phlebology. 2010 Oct;25 Suppl 1:35-41. doi: 10.1258/phleb.2010.010s06. Review.
• 13. Ultrasound-promoted enzymatic synthesis of troxerutin esters in nonaqueous solvents.
  Xiao Y, Yang L, Mao P, Zhao Z, Lin X.Ultrason Sonochem. 2011 Jan;18(1):303-9. doi: 10.1016/j.ultsonch.2010.06.010. Epub 2010 Jul 1.
• 14. Chronic administration of troxerutin protects mouse kidney against D-galactose-induced oxidative DNA damage.
  Liu CM, Ma JQ, Lou Y.Food Chem Toxicol. 2010 Oct;48(10):2809-17. doi: 10.1016/j.fct.2010.07.011. Epub 2010 Jul 13.
• 15. NGF-Dependent activation of TrkA pathway: A mechanism for the neuroprotective effect of troxerutin in D-galactose-treated mice.
  Lu J, Wu DM, Hu B, Zheng YL, Zhang ZF, Wang YJ.Brain Pathol. 2010 Sep;20(5):952-65. doi: 10.1111/j.1750-3639.2010.00397.x. Epub 2010 Mar 19.
• 16. Calcium dobesilate and oxerutin: effectiveness of combination therapy.
  Akbulut B.Phlebology. 2010 Apr;25(2):66-71. doi: 10.1258/phleb.2009.008085.
• 17. [Urgent urinary incontinence due to taking troxerutine sachets].
  Aroca García D, Gómez Rivas P.Aten Primaria. 2010 Dec;42(12):626-8. doi: 10.1016/j.aprim.2010.01.009. Epub 2010 Mar 19. Spanish.  No abstract available.
• 18. Conversion from nonischemic to ischemic retinal vein occlusion: prediction by venous velocity on color Doppler imaging.
  Arsene S, Vierron E, Le Lez ML, Herault B, Gruel Y, Pisella PJ, Giraudeau B, Tranquart F.Eur J Ophthalmol. 2009 Nov-Dec;19(6):1009-16.
• 19. Chronic administration of troxerutin protects mouse brain against D-galactose-induced impairment of cholinergic system.
  Lu J, Wu DM, Hu B, Cheng W, Zheng YL, Zhang ZF, Ye Q, Fan SH, Shan Q, Wang YJ.Neurobiol Learn Mem. 2010 Feb;93(2):157-64. doi: 10.1016/j.nlm.2009.09.006. Epub 2009 Sep 17.
• 20. Troxerutin protects the mouse liver against oxidative stress-mediated injury induced by D-galactose.
  Zhang ZF, Fan SH, Zheng YL, Lu J, Wu DM, Shan Q, Hu B.J Agric Food Chem. 2009 Sep 9;57(17):7731-6. doi: 10.1021/jf9012357.

Details